Perlecan/Hspg2 deficiency alters the pericellular space of the lacunocanalicular system surrounding osteocytic processes in cortical bone

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 618-629

  Thompson, William R ^a   Modla, Shannon ^a   Grindel, Brian J ^b   Czymmek, Kirk J ^a   Kirn Safran, Catherine B ^a   Wang, Liyun ^a   Duncan, Randall L ^a   Farach Carson, Mary C ^a,b  

^a UNIVERSITY OF DELAWARE   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

cortical bone; heparan sulfate; lacunocanalicular system; mechanosensing; Osteocyte; perlecan HSPG2

Indexed keywords

PERLECAN; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MATRIX; BONE MINERALIZATION; CELL COMMUNICATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CORTICAL BONE; EFFECTOR CELL; GENE; HSPG2 GENE; IMMUNOFLUORESCENCE; IMMUNOGOLD STAINING; INTERSTITIAL FLUID; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUTRIENT; OSTEOCYTE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BONE AND BONES; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; INTRACELLULAR SPACE; MICE; MOLECULAR WEIGHT; OSTEOCYTES; PROTEIN TRANSPORT; RNA, MESSENGER;

EID: 79951844176     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.236     Document Type: Article

References (53)

1. Duncan RL, Turner CH,. Mechanotransduction and the functional response of bone to mechanical strain. Calcif Tissue Int. 1995; 57: 344-358.
2. Parfitt AM,. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res. 1977; 127: 236-247. (Pubitemid 8192287)
3. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007; 5: 464-475. (Pubitemid 46825494)
4. Noble BS,. The osteocyte lineage. Arch Biochem Biophys. 2008; 473: 106-111.
5. Cowin SC,. Mechanosensation and fluid transport in living bone. J Musculoskel Neuronal Interact. 2002; 2: 256-260. (Pubitemid 34223816)
6. Piekarski K, Munro M,. Transport mechanism operating between blood supply and osteocytes in long bones. Nature. 1977; 269: 80-82. (Pubitemid 8160686)
7. You L, Cowin SC, Schaffler MB, Weinbaum S,. A model for strain amplification in the actin cytoskeleton of osteocytes due to fluid drag on pericellular matrix. J Biomech. 2001; 34: 1375-1386. (Pubitemid 32970752)
8. You LD, Weinbaum S, Cowin SC, Schaffler MB,. Ultrastructure of the osteocyte process and its pericellular matrix. Anat Rec A Discov Mol Cell Evol Biol. 2004; 278: 505-513. (Pubitemid 38724147)
9. Inoue K, Mikuni-Takagaki Y, Oikawa K, et al. A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism. J Biol Chem. 2006; 281: 33814-33824. (Pubitemid 46036758)
10. Sauren YM, Mieremet RH, Groot CG, Scherft JP,. An electron microscopic study on the presence of proteoglycans in the mineralized matrix of rat and human compact lamellar bone. Anat Rec. 1992; 232: 36-44.
11. Kirn-Safran C, Farach-Carson MC, Carson DD,. Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci. 2009; 66: 3421-3434.
12. Farach-Carson MC, Carson DD,. Perlecan-a multifunctional extracellular proteoglycan scaffold. Glycobiology. 2007; 17: 897-905. (Pubitemid 47423879)
13. Noonan DM, Fulle A, Valente P, et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem. 1991; 266: 22939-22947. (Pubitemid 21908742)
14. Kallunki P, Tryggvason K,. Human basement membrane heparan sulfate proteoglycan core protein: a 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Cell Biol. 1992; 116: 559-571.
15. Noonan DM, Horigan EA, Ledbetter SR, et al. Identification of cDNA clones encoding different domains of the basement membrane heparan sulfate proteoglycan. J Biol Chem. 1988; 263: 16379-16387. (Pubitemid 18262059)
16. Tapanadechopone P, Hassell JR, Rigatti B, Couchman JR,. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun. 1999; 265: 680-690.
17. Iozzo RV,. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol. 2005; 6: 646-656. (Pubitemid 41081268)
18. Hayashi K, Madri JA, Yurchenco PD,. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol. 1992; 119: 945-959.
19. Bix G, Fu J, Gonzalez EM, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol. 2004; 166: 97-109. (Pubitemid 38931920)
20. Bix G, Iozzo RA, Woodall B, et al. Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the alpha2beta1-integrin receptor. Blood. 2007; 109: 3745-3748. (Pubitemid 46641724)
21. Woodall BP, Nystrom A, Iozzo RA, et al. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J Biol Chem. 2008; 283: 2335-2343.
22. Vincent TL, McLean CJ, Full LE, Peston D, Saklatvala J,. FGF-2 is bound to perlecan in the pericellular matrix of articular cartilage, where it acts as a chondrocyte mechanotransducer. Osteoarthritis Cartilage. 2007; 15: 752-763. (Pubitemid 46888165)
23. Hasengaowa Kodama J, Kusumoto T, Shinyo Y, et al. Loss of basement membrane heparan sulfate expression is associated with tumor progression in endometrial cancer. Eur J Gynaecol Oncol. 2005; 26: 403-406. (Pubitemid 41139468)
24. Kodama J, Shinyo Y, Hasengaowa Kusumoto T, et al. Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol Rep. 2005; 14: 89-92.
25. Deguchi Y, Okutsu H, Okura T, et al. Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J Neurochem. 2002; 83: 381-389. (Pubitemid 35191403)
26. Morita H, Yoshimura A, Inui K, et al. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol. 2005; 16: 1703-1710. (Pubitemid 41716476)
27. Kasinath B, Kanwar Y,. Molecular and Cellular Aspects of Basement Membranes. 1993.
28. Hoh JH,. Functional protein domains from the thermally driven motion of polypeptide chains: a proposal. Proteins. 1998; 32: 223-228. (Pubitemid 28363903)
29. Chen CH, Hansma HG,. Basement membrane macromolecules: insights from atomic force microscopy. J Struct Biol. 2000; 131: 44-55.
30. Rees SG, Hughes W, Embery G,. Interaction of glucuronic acid and iduronic acid-rich glycosaminoglycans and their modified forms with hydroxyapatite. Biomaterials. 2002; 23: 481-489. (Pubitemid 33051036)
31. Yang L, Butcher M, Simon RR, Osip SL, Shaughnessy SG,. The effect of heparin on osteoblast differentiation and activity in primary cultures of bovine aortic smooth muscle cells. Atherosclerosis. 2005; 179: 79-86. (Pubitemid 40249788)
32. McNamara LM, Majeska RJ, Weinbaum S, Friedrich V, Schaffler MB,. Attachment of osteocyte cell processes to the bone matrix. Anat Rec (Hoboken). 2009; 292: 355-363.
33. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF,. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res. 1997; 12: 2014-2023. (Pubitemid 27524478)
34. Iozzo RV,. Biosynthesis of heparan sulfate proteoglycan by human colon carcinoma cells and its localization at the cell surface. J Cell Biol. 1984; 99: 403-417. (Pubitemid 14065166)
35. Gomes RR Jr, Joshi SS, Farach-Carson MC, Carson DD,. Ribozyme-mediated perlecan knockdown impairs chondrogenic differentiation of C3H10T1/2 fibroblasts. Differentiation. 2006; 74: 53-63.
36. Brown AJ, Alicknavitch M, D'Souza SS, et al. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone. 2008; 43: 689-699.
37. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA,. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem. 1996; 271: 10079-10086. (Pubitemid 26131567)
38. Rodgers KD, Sasaki T, Aszodi A, Jacenko O,. Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome. Hum Mol Genet. 2007; 16: 515-528. (Pubitemid 46522614)
39. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y,. Perlecan is essential for cartilage and cephalic development. Nat Genet. 1999; 23: 354-358. (Pubitemid 29526437)
40. Costell M, Gustafsson E, Aszodi A, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol. 1999; 147: 1109-1122.
41. Rostgaard J, Qvortrup K,. Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res. 1997; 53: 1-13. (Pubitemid 27204878)
42. Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R,. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem. 1997; 250: 39-46. (Pubitemid 27504580)
43. Reilly GC, Haut TR, Yellowley CE, Donahue HJ, Jacobs CR,. Fluid flow induced PGE2 release by bone cells is reduced by glycocalyx degradation whereas calcium signals are not. Biorheology. 2003; 40: 591-603. (Pubitemid 37510371)
44. Smith AJ, Singhrao SK, Newman GR, Waddington RJ, Embery G,. A biochemical and immuno-electron microscopical analysis of chondroitin sulphate-rich proteoglycans in human alveolar bone. Histochem J. 1997; 29: 1-9. (Pubitemid 27173643)
45. Takagi M, Ono Y, Maeno M, Miyashita K, Omiya K,. Immunohistochemical and biochemical characterization of sulphated proteoglycans in embryonic chick bone. J Nihon Univ Sch Dent. 1997; 39: 156-163.
46. Murakami T, Hitomi S, Ohtsuka A, Taguchi T,. Neurons with perineuronal sulfated proteoglycans in the human visual cortex, with special reference to their reactions to lectins. Arch Histol Cytol. 1995; 58: 357-364.
47. Henry CB, Duling BR,. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol. 1999; 277 (2 Pt 2): H508-514. (Pubitemid 29415963)
48. Howell DS, Pita JC,. Calcificaiton of growth plate cartilage with special reference to studies on micropuncture fluids. Clin Orthop Relat Res. 1976; 118: 208-229.
49. Chen CC, Boskey AL,. Mechanisms of proteoglycan inhibition of hydroxyapatite growth. Calcif Tissue Int. 1985; 37: 395-400. (Pubitemid 15022724)
50. Chen CC, Boskey AL, Rosenberg LC,. The inhibitory effect of cartilage proteoglycans on hydroxyapatite growth. Calcif Tissue Int. 1984; 36: 285-290. (Pubitemid 14072396)
51. French MM, Smith SE, Akanbi K, et al. Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol. 1999; 145: 1103-1115. (Pubitemid 29270066)
52. Knothe Tate ML, Adamson JR, Tami AE, Bauer TW,. The osteocyte. Int J Biochem Cell Biol. 2004; 36: 1-8. (Pubitemid 37338467)
53. Zhou X, Novotny JE, Wang L,. Anatomic variations of the lacunar-canalicular system influence solute transport in bone. Bone. 2009; 45: 704-710.